Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations by Lakatos, Péter László et al.
• BASIC RESEARCH •
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian
patients with Crohn’s disease: Phenotype-genotype correlations
Peter Laszlo Lakatos, Laszlo Lakatos, Ferenc Szalay, Claudia Willheim-Polli, Christoph Österreicher, Zsolt Tulassay,
Tamas Molnar, Walter Reinisch, Janos Papp, Gyula Mozsik, Hungarian IBD Study Group, Peter Ferenci
ELSEVIER
PO Box 2345, Beijing 100023, China                                                                                                                                                          World J Gastroenterol  2005;11(10):1489-1495
www.wjgnet.com                                                                                                              World Journal of Gastroenterology  ISSN 1007-9327
wjg@wjgnet.com                                                                                                                                                                                       © 2005 The WJG Press and Elsevier Inc. All rights reserved.
Peter Laszlo Lakatos, Ferenc Szalay, Janos Papp, Hungarian
IBD Study Group, 1st Department of Medicine, Semmelweis
University, Budapest, Hungary
Laszlo Lakatos, 1st Department of Medicine, Csolnoky F. County
Hospital, Veszprem, Hungary
Claudia Willheim-Polli, Christoph Österreicher, Walter Reinisch,
Peter Ferenci, Department of Internal Medicine 4, University of
Vienna, Austria
Zsolt Tulassay, 2nd Department of Medicine, Semmelweis
University, Budapest, Hungary
Tamas Molnar, 1st Department of Medicine, University of Szeged,
Szeged, Hungary
Gyula Mozsik, 1st Department of Medicine, University of Pecs,
Pecs, Hungary
Hungarian IBD Study Group: Semmelweis University, 1st
Department of Medicine, Budapest: Peter Fuszek, Peter Vargha;
Semmelweis University, 2nd Department of Medicine, Semmelweis
University, Budapest: Laszlo Pronai†, Annamaria Nemeth, Pal Miheller;
Erzsebet Hospital, 1st Department of Medicine, Budapest: Agota
Kovacs, Laszlo Bene; Szent Janos Hospital, 1st Department of Medicine:
Gyorgy Szekely; University of Pecs, 1st Department of Medicine,
Pecs: Beata Gasztonyi; University of Szeged, 1st Department of
Medicine, Szeged: Ferenc Nagy, Janos Lonovics; Semmelweis Hospital,
1st Department of Medicine, Miskolc: Laszlo Ujszaszy; University
of Debrecen, 2nd Department of Medicine, Debrecen: Istvan Altorjai,
Karoly Palatka; Kenezi Gy. County Hospital, 2nd Department of
Medicine, Debrecen: Gyula G. Kiss; County Hospital, 2nd
Department of Medicine, Zalaegerszeg; Ferenc Tarnok, Markusovszky
Hospital, 2nd Department of Medicine, Szombathely: Zoltan Dobronte;
Csolnoky F. County Hospital, 1st Department of Medicine,
Veszprem: Zsuzsanna Erdelyi, Tunde Pandur, Gabor Mester
Correspondence to: Peter Laszlo Lakatos, M.D., Ph.D., 1st
Department of Medicine, Semmelweis University, Koranyi str. 2/A,
H-1083, Hungary.  kislakpet@bel1.sote.hu
Telephone: +36-1-210-0278/1500-1520    Fax: +36-1-313-0250
Received: 2004-07-26    Accepted: 2004-09-09
Abstract
AIM: To determine common NOD2/CARD15 mutations and
TLR4 D299G polymorphism in Hungarian patients with CD.
METHODS: A total of 527 unrelated patients with CD
(male/female: 265/262, age: 37.1 (SD 7.6) years) and
200 healthy subjects were included. DNA was screened
for possible NOD2/CARD15 mutations by denaturing high-
performance liquid chromatography (confirmed by direct
sequencing). TLR4 D299G was tested by PCR-RFLP.
RESULTS: NOD2/CARD15 mutations were found in 185
patients (35.1%) and in 33 controls (16.5%, P<0.0001).
SNP8/R702W (10.8% vs 6%, P = 0.02), SNP13/3020insC
(19.4% vs 5%, P<0.0001) and exon4 R703C (2.1% vs
0%, P = 0.02) mutations were more frequent in CD, while
the frequency of SNP12/G908R was not increased. The
frequency of TLR4 D299G was not different (CD: 9.9% vs
controls: 12.0%). Variant NOD2/CARD15 allele was
associated with an increased risk for CD (ORhet = 1.71,
95%CI = 1.12-2.6, P = 0.0001, ORtwo-risk alleles = 25.2,
95%CI = 4.37-    , P<0.0001), early disease onset (carrier:
26.4 years vs non-carrier: 29.8 years, P = 0.0006), ileal
disease (81.9% vs 69.5%, OR = 1.99, 95%CI = 1.29-3.08,
P = 0.02, presence of NOD2/CARD15 and TLR4: 86.7% vs
64.8%), stricturing behavior (OR = 1.69, 95%CI = 1.13-2.55,
P = 0.026) and increased need for resection (OR=1.71,
95%CI: 1.13-2.62, P = 0.01), but not with duration, extra-
intestinal manifestations, familial disease or smoking. TLR4
exhibited a modifier effect: age of onset in wt/TLR4 D299G
carriers: 27.4 years vs NOD2mut/TLR D299G: 23 years
(P = 0.06), in NOD2mut/wt: 26.7 years.
CONCLUSION: These results confirm that variant NOD2/
CARD15 (R702W, R703C and 3020insC) alleles are
associated with earlier disease onset, ileal disease,
stricturing disease behavior in Hungarian CD patients. In
contrast, although the frequency of TLR4 D299G
polymorphism was not different from controls, NOD2/TLR4
mutation carriers tended to present at earlier age.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a multifactorial
polygenic disease with probable genetic heterogeneity. In
addition to genetic predisposition, various environmental
and host factors (e.g. genetic, epithelial, immune and non-
immune factors) play a major role in the pathogenesis of
IBD. Crohn’s disease (CD) is a chronic inflammatory disorder
of the gastrointestinal tract. Extensive heterogeneity is
observed in terms of  disease presentation, behavior, and
response to treatment[1,2 ]. Attempts have been made to define
clinical subgroups on the basis of age at onset, disease
location, extent (diffuse or localized) and behavior (primary
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inflammatory, fistulating, or fibrostenotic).
CD has a strong genetic component, with a lifetime risk
of 10-20% to develop IBD in the presence of an affected
first-degree relative[1]. The concordance rate of affected
siblings for age at onset, disease site, behavior and presence
of extra-intestinal manifestation is as high as 80%. Since
the first report of Hugot et al.[3] in 1996, seven IBD loci
have been identified on chromosomes 16q12 (IBD1), 12q13
(IBD2), 6p13 (IBD3), 14q11 (IBD4), 5q31-33 (IBD5),
19p13 (IBD6) and 1p (IBD7)[4-6]. These seven loci are
convincingly replicated. Some genetic markers increase the
risk of ulcerative colitis or CD while others are associated
with a particular phenotypic expression like disease location
and/or behavior. The NOD2/CARD15 gene is located in
the IBD1 region. NOD2/CARD15 is a cytoplasmatic protein
expressed in peripheral blood monocytes, Paneth cells and
intestinal epithelial cells and is related structurally to the well-
described R proteins in plants, which mediate host resistance
to microbial pathogens[7] and induce the NF-κB pathway[8].
Variant alleles result in reduced NF-κB activity[9]. Variant
NOD2/CARD15 alleles are also associated with reduced
α-defensin release from Paneth cells in response to bacteria[10].
Of  particular importance is the C-terminus leucine-rich repeat
domain, reportedly the major structural motif that functions
as a pattern-recognition receptor for broad types of microbial
components, such as bacterial lipopolysaccharides (LPS) and
peptidoglycan (including MDP)[11].
Two single nucleotide polymorphisms of  NOD2/
CARD15 (SNP8: Arg702Trp and SNP12: Gly908Arg) and
a frame shift mutation (SNP13: Leu1007insC) have been
shown by three independent groups to be associated with
susceptibility to CD[12-14]. The presence of one variant allele
increases the risk for developing CD 1.5-4.3-fold, and the
presence of two copies up to 20-40-fold[13-15]. It has also
been suggested that the presence of  variant alleles is
associated with ileal disease and fibrostenosing or fistulizing
behavior in some[15,16], but not in all the studies[17,18].
However, there are significant geographical differences
in the frequency of these alleles. They are not found in
Japan and China[19,20] and are less frequent in Finland[21]
than in Western Europe. There are only limited data in patients
from Central-Eastern European countries like Hungary. The
incidence of CD in Hungary has been steadily elevat in the
last decades (from 0.41 in 1977-1981 to 4.68 in 1997-2001),
now reaching that of  Western European countries.
Toll-like receptors (TLRs) expressed in myeloid cells play
a major role both in detecting microbes and in initiating
innate immune responses. In contrast, little is known
concerning the expression, distribution and function of TLRs
in epithelial cells per se. Toll-like receptor 4 (TLR4) is also
expressed in the Golgi apparatus of intestinal epithelial cells.
Thus, LPS recognition in intestinal epithelial cells may occur
in the Golgi apparatus and require LPS internalization[22].
Recently it has been suggested that the interaction of  LPS
with TLR4/MD2 contributes to the perpetuation of the
inflammatory epithelial cell injury via TNFα-induced
alterations of enterocyte turnover in an autoparacrine/
paracrine manner[23]. TLRs may also influence the nature
of the immune response, in particular by skewing T cells
toward a Th1 or Th2 profile. Myeloid cells are exquisitely
sensitive to TLR ligands and produce significant IL-12p40
and appear to play key roles in the initiation and possibly
the Th1/Th2 skewing of inflammatory responses. In this
model the inflammation would normally be controlled by
myeloid or lymphocyte-derived IL-10 acting through Stat3
in myeloid cells to block further production of IL-12/IL-
23 and skewing to Th1 response[24].
TLR4 is upregulated in the intestinal epithelial cells in
patients with CD. In contrast, the expressions of TLR2
and TLR5 are unchanged, while TLR3 is down-regulated[25].
The D299G (Asp299Gly) polymorphism of TLR4 gene is
associated with LPS hyporesponsiveness[26] and recently an
association between TLR4 mutation and CD was reported
in one study[27], but not in another[28].
In view of the limited data on the prevalence of
NOD2/CARD15 mutations in Eastern European countries,
our aim was to investigate the presence of the common
three and other exon4 variants of NOD2/CARD15 as well
as the presence of functional D299G polymorphism of the
TLR4 gene in three large cohorts of Hungarian patients with
CD. We also aimed to investigate the possible association
between genotype and clinical characteristics of the disease.
MATERIALS AND METHODS
Patients
A total of 527 unrelated Hungarian patients with CD [male/
female: 265/262, age: 37.1 (SD 7.6) years] were investigated.
The patients were recruited from three Hungarian IBD
centers (Szeged [n = 167], Budapest [n = 185], Veszprem
[n = 175]). CD patients, with a follow-up time of at least
one year were included. The diagnosis was based on the
Lennard-Jones criteria[29]. The clinical characteristics of the
patients are summarized in Table 1. The disease phenotype
Table 1  Clinical characteristics of the different cohorts of Crohn’s
disease (CD) patients
                   Budapest Veszprem  Szeged
 (n = 185)    (n = 175) (n = 167)
Male/Female     98/87       88/87    79/88
Age (yr) 35.6±11.4   37.8±13.3 37.1±12.7
Age at presentation (yr) 27.2±10.3   30.2±12.4 28.9±10.9
Duration (yr)   8.9±6.6      7.7±6.8   8.0±7.3
Familial IBD, n (%)  63 (11.9)    38 (11.1)  25 (13.5)
Location (n) L1         43           54         39
L2         37           47         52
L3      103           74         74
L4         2           0         2
Behavior (n) B1         88           65         62
B2         40           39         49
B3         56           71         56
Perianal disease, n (%)  41 (22.1)    49 (28.0)  50 (29.9)
Frequent relapse, n (%)  59 (31.9)    72 (41.1)  64 (38.6)
Extraintestinal  67 (36.2)    61 (34.8)  47 (28.2)
manifestations, n (%)
Operation, n (%)  77 (41.6)    76 (43.4)  67 (40.1)
Smoking habits (n) No      115           96         98
                                       Yes         55           61         55
                                      Previous        15           20         14
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(age at onset, duration, location and behavior) was determined
according to the Vienna classification[30]. Perianal involvement,
presence of extraintestinal manifestations (EIM; arthritis:
peripheral and axial; ocular manifestations: conjunctivitis,
uveitis, iridocyclitis; skin lesions: erythema nodosum,
pyoderma gangrenosum; hepatic manifestations: primary
sclerosing cholangitis [PSC]), frequency of flare-ups
(frequent flare-up: >1/year), therapeutic effectiveness (e.g.
steroid and/or immunosuppressive resistance), need for
surgery (resections). Presence of familial IBD and smoking
habits were investigated by filling in a questionnaire.
The control group for mutation analysis consisted of
200 age- and gender-matched healthy subjects [male/female:
102/98, age: 38.05 (SD 10.7) years]. The study was approved
by the Semmelweis University Regional and Institutional
Committee of Science and Research Ethics (81/2003). Each
patient was informed of  the nature of  the study and signed
the informed consent form.
Detection of NOD2/CARD15 SNP8, 12, 13 and exon4 mutations
Genomic DNA was isolated from whole blood according
to the QIAamp DNA blood mini kit (QIAGEN GmbH,
Germany). Each exon was amplified by PCR using previously
published primer sequences[17]. The initial denaturation step
(at 94  for 7 min) was to activate AmpliTaq Gold (Applied
Biosystems, Foster City, CA, USA), followed by 33 cycles
(at 94  for 20 s, at 61  for 30 s, at 72  for 25 s) with
a final extension step at 72  for 7 min. Then denaturing
high-performance liquid chromatography (dHPLC, wave
DNA fragment analysis system, Transgenomic Limited, UK)
were performed to analyze the exons. PCR products were
denatured as a last step at 94  for 5 min to induce
heteroduplex formation during the following 30 min of
slowly cooling down to room temperature. Five microliters
of these PCR products were then automatically loaded onto
the DNASep cartridge (Transgenomic Limited, UK) in the
wave system. The specific acetonitrile gradient to elute each
exon was established by using the WaveMaker 3.4.4 software.
The particular run temperature for the detection of each
SNP was determined using positive controls, which were
kindly provided by Dirk Seegert from Kiel, Germany.
Finally, when a sequence variation was observed in the
dHPLC profile, the relevant PCR product was sequenced
on both strands to confirm the alteration. Sequencing
reactions were performed with the ABI BigDye terminator
cycle sequencing kit v1.1 (Applied Biosystems) and samples
were sequenced on an ABI Prism 310 genetic analyzer
(Applied Biosystems).
Detection of TLR4 D299G polymorphism
The TLR4 D299G polymorphism was detected by PCR-
RFLP (PTC-200 thermocycler, MJ Research Inc., MA,
USA) using previously published primers and conditions[31].
For the overnight digestion of  the amplified DNA, NcoI
enzyme (New England Biolabs, London, UK) was used and
the fragments were separated and visualized by gel
electrophoresis (3% NuSieve® GTG agarose gel BMA,
Rockland, ME, USA).
Statistical analysis
Variables were tested for normality by Shapiro Wilk’s
W test. t-test with separate variance estimates, χ2-test and
χ2-test with Yates correction were used to test differences
between patients with CD and controls, and also within
subgroups of CD patients. Odds ratios (OR) and logistic
regression were calculated to compare genetic and clinical
data. P<0.05 was considered statistically significant. For the
statistical analysis, Statistica 6.1 (Statsoft Inc., OK, USA)
was used.
RESULTS
NOD2/CARD15 mutations were more frequently found
in CD patients (185/527; 35.1%) than those in controls
(16.5%, P<0.0001, Table 2). Heterozygous (ORhet = 1.71;
95%CI = 1.12-2.6, P = 0.0001), homozygous (ORhom = 14.43;
95%CI = 2.47-   , P = 0.0003) or compound heterozygous
(ORcompound = 12.92; 95%CI = 2.2-   , P = 0.0006) carriage
of a variant allele was associated with increased risk for
CD. The OR for carrying two variant alleles was 25.2
(95%CI: 4.35-   , P<0.0001). SNP8 (11.6% vs controls:
6%) and SNP13 (19.4% vs controls: 5%, P<0.0001)
mutations were more frequent in CD (Table 3), while the
frequency of SNP12 variant allele was not different, but
consistent in different cohorts (Table 4). The carriage of
SNP8, SNP13 (ORSNP8 allele = 2.41; 95%CI = 1.30-4.44,
ORSNP13 allele = 4.78; 95%CI = 2.50-9.11) and a further exon4
variant allele (R703CCD: 2.1% vs controls: 0%, OR = 6.89;
95%CI = 1.18-   , P = 0.02) were identified as risk factors
for CD (Tables 3 and 5).
Table 2  NOD2/CARD15 and TLR4 D299G genotype in patients with Crohn’s disease (CD) and controls, n (%)
   NOD2 genotype
A
Non-carrier               All carrier     Heterozygous Homozygous                Compound heterozygous
Controls (n = 200)   167 (83.5)                 33 (16.5)          33 (16.5)            0     0
CD (n = 527)   342 (64.9)              185 (35.1)       133 (25.2)1        30 (5.7)2                  26 (4.9)3
           TLR4 D299G
B
                Non-carrier                 All carrier              Heterozygous Homozygous
Controls (n = 200) 176 (88.0) 24 (12.0) 23 (11.5)          1 (0.5)
CD (n = 527) 475 (90.1) 52 (9.9) 50 (9.5)          2 (0.4)
P<0.0001 between CD patients and controls, 1ORhet = 1.71 (1.12–2.60), 2ORhom = 14.43 (2.47–     ), 3ORcompound = 12.92 (2.2–     ).
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More homozygous (60%) or compound heterozygous
(69.2%) patients tended to be females compared to
heterozygous (46.6%) patients and non-carriers (49.1%).
The use of immunosuppressive drugs (P = 0.04) and the
need for surgery (resection, P = 0.006) were more frequent
in carriers of  the mutation (Table 6). The percentage of
patients with resection was even higher in compound
heterozygous patients (65.4%, 17/26, P = 0.006 compared
to non-carriers by Fischer exact test). The presence of
variant NOD2/CARD15 allele affected disease phenotype
and was associated with earlier disease onset (26.4 vs 29.8 years,
P = 0.0006), the site of involvement (ileal involvement:
81.6% vs non-carriers: 69.0%, OR = 1.99, 95%CI: 1.29-3.08,
P = 0.02) and with stricturing behavior (OR =  1.69, 95%CI:
1.13-2.55, P = 0.02, Tables 6, 7). The presence of  NOD2/
CARD15 variant alleles was not associated with the presence
of perianal manifestation associated disease duration, more
frequent relapses, familial disease and presence of EIMs or
smoking habits. EIMs were tendentiously even less frequent
in patients carrying two mutant alleles.
Table 3 NOD2/CARD15 SNP8, 12 and 13 in patients with Crohn’s disease (CD) and controls
     R702W (SNP8)1     G908R (SNP12)              3020insC (SNP13)1
 CD n (%)               Controls n (%)  CD n (%)               Controls n (%) CD n (%)  Controls n (%)
Wild type 466 (88.4) 188 (94.0) 494 (96.7) 193 (96.5) 425 (80.6)       190 (95.0)
All carriers    61 (11.6)    12 (6.0)    33 (6.3)      7 (3.5) 102 (19.4)          10 (5.0)
Heterozygous    45 (8.5)    12 (6.0)    33 (6.3)      7 (3.5)   89 (16.9)          10 (5.0)
Homozygous    16 (3.1)        0        0         0    13 (2.5)             0
1P = 0.02 and P<0.0001 between patients and controls for genotype frequency by χ2-test, ORSNP8 allele = 2.41 (1.30–4.44), ORSNP13 allele = 4.78 (2.50–9.11).
Table 4  NOD2/CARD15 and TLR4 D299G mutations in different
cohorts of CD patients, n (%)
                  Budapest                  Veszprem  Szeged
(n = 185) (n = 175) (n = 167)
NOD2/CARD15 64 (34.6)1 61 (34.9)1 60 (35.9)1
SNP8 17 (9.2) 23 (13.1)2 21 (12.6)3
SNP12 12 (6.5) 10 (5.7) 11 (6.6)
SNP13 39 (21.1)1 33 (18.9)1 30 (18.0)4
TLR4 D299G 21 (11.4) 20 (11.4) 11 (6.6)
1P<0.0001, 2P = 0.0002, 3P = 0.0005, 4P = 0.04 cohort vs controls (Tables 2, 3).
Table 5  Further exon4 mutations in patients with Crohn’s disease
(CD) and controls
       CD (n = 527)             Controls (n = 200)
R703C1 11 (1 homozygous)         0
R713C 1         0
A755V 2         1
E778K 0         1
R791Q 5         1
V793M 2         1
1P = 0.02 between patients and controls for allele frequency, ORR703C = 6.89 (1.18–    ).
Table 6  Clinical characteristics of CD patients, with respect to the presence or absence of NOD2/CARD15 mutations
            Total (n = 527)        Non carrier (n = 342)             Carrier (n = 185)           1 allele (n = 133)            2 alleles (n = 52)
Male/Female 265/262  174/168     91/94     71/62    20/32
Age (yr) 36.9±9.1 37.9±13.0 34.9±11.61 35.2±11.7 34.3±11.4
Age at presentation (yr) 37.1±7.6 29.8±12.1 26.4±9.71 26.4±9.6 26.5±10.2
Duration (yr)    8.2±5.0   8.1±7.0   8.5±6.7   8.8±7.0   7.9±5.8
Familiar IBD n (%)   63 (11.9)  38 (11.1) 25 (13.5) 17 (12.8)   8 (15.4)
Location (n) L1        136        84        521        362         162
L2        136      103        33        26         7
L3        251      152        99        71         28
L4          4         3         1        0         1
Behavior (n) B1        216      151        651        483         17
B2        128        71        57        42         15
B3        183      120        63        43         20
Perianal disease n (%) 140 (26.6)  89 (26.0) 51 (27.6) 36 (27.1) 15 (28.9)
Frequent relapse n (%) 195 (37.1)                  126 (36.9) 69 (37.3) 47 (35.3) 22 (42.3)
Extraintestinal manifestations n (%) 175 (33.2)                  117 (34.2) 58 (31.3) 45 (33.8) 13 (25)
Arthritis n (%) 147 (27.9)  98 (28.7) 49 (26.5) 36 (27.1) 13 (25)
Occular n (%)   27 (5.1)  18 (5.2)   9 (4.9)   9 (6.8)         0
Erythema
nodosum/Pyoderma n (%)   48 (9.1)  30 (8.8) 18 (9.7) 15 (11.3) 3 (5.8)
PSCa   18 (3.4)  15 (4.4)   3 (1.6)   3 (2.3)         0
Steroid use/ 440 (83.5)/                  282 (82.4)/                  158 (85.4)/                  114 (85.7)/ 44 (84.6)/
refractory n (%) 44 (10)  28 (9.3) 16 (10.1) 10 (8.8) 6 (13.6)
Azathioprine use/ 337 (64.1)/                  208 (60.8)/                  129 (69.7)1/ 89 (66.9)/ 40 (76.9)4/
refractory n (%)   19 (5.6)  10 (4.8)   9 (7.0)   7 (7.8)   2 (5)
Operation n (%) 220 (41.8)                  128 (37.4) 92 (49.7)1 66 (49.6)2 26 (50.0)2
Smoking (n) Never        308      191      117        80         37
Active        170      115        55        42         13
Previous          49        36        13        11         2
1P<0.03 between carriers and non-carriers, 2P<0.03 between patients carrying one or two mutant allele and non-carriers, 3P = 0.043 between patients carrying one
mutant allele and non-carriers, 4P = 0.025 between patients carrying two mutant allele and non-carriers.
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The TLR4 D299G mutation was not different between
patients and controls (9.9% vs 12.0%, P = NS). The
frequency of familial IBD tended to be lower in patients
with TLR4 mutation (5.7% vs without 12.6%, P = NS).
However, the presence of variant TLR4 allele strengthened
genotype-phenotype associations (Figure 1; for age of onset:
non-carriers [n = 305]: 30.2 years, only TLR4 carriers
[n = 37]: 27.4 years, only NOD2/CARD15 carriers [n = 170]:
26.7 years, both NOD2 and TLR4 carriers [n = 15]: 23 years,
P = 0.03 for NOD2/CARD15 variant allele, and P = 0.06
for TLR4 variant allele by multiple regression and for ileal
involvement; in patients with TLR4 and NOD2/CARD15
mutations: 86.7% vs non-carriers: 64.8%).
In a logistic regression model, exploring the effect of
NOD2, TLR4 carriage, age at presentation, location, behavior
and smoking, presence of NOD2 mutation (coefficient =
0.54, OR = 1.71, 95%CI: 1.13-2.62, P = 0.01) and non-
inflammatory behavior (coefficient = 1.26, OR = 3.53,
95%CI: 2.76-4.51, P = 0.001) but not location, smoking or
carriage of TLR4 variant allele were independently
associated with the need for surgery. However, the
percentage of multiple resections was not different between
carriers and non-carriers (13.0% vs 11.1%, P = NS).
DISCUSSION
This is the first report on the prevalence of NOD2/
CARD15 mutations and TLR4 D299G polymorphism in
patients with CD from a Central Eastern European country.
The reported rates of 35.1% of patients carrying NOD2/
CARD15 mutations in CD and 16.5% in controls are in
concordance with previously reported rates of 30-50%
in CD and 7-20% in controls from other European
regions[12,15-17,32-35]. Only in Finland (which by language is
related to Hungary), the rate of NOD2 mutations was
considerably lower (8.7% vs 3.5% in controls)[21]. Similar
low frequencies were found in other Northern European
countries (8% in Denmark, and 8.9% in patients from
Norway)[28]. The prevalence of SNP8, 12 and 13 was 3.3,
0.6 and 4.8% in the Finish study (in controls it was 1.8%, 0
and 1.7%) with only the SNP13 being more common in
CD compared to controls. In our study, the rates were 11.6,
Table 7  Genotype–phenotype associations with particular NOD2/CARD15 alleles in CD patients
             None (n = 342)                SNP8 (n = 61)              SNP12 (n = 33)            SNP13 (n = 102)
Male/Female  174/168    28/33     14/19    51/51
Age (yr) 37.9±13.0 35.9±13.0 37.1±11.4 33.7±10.41
Age at presentation (yr) 29.8±12.1 26.6±10.9 28.8±10.0 26.0±8.41
Duration (yr)   8.1±7.0   9.3±7.6 11.4±6.42    7.7±6.1
Familiar IBD n (%)  38 (11.1)   9 (14.8)  7 (21.1)  11 (10.8)
Location L1         84        16       7        322
L2      103        12       5        16
L3      152        33      20        53
L4         3        0       1         1
Behavior B1      151        22       8        34
B2         71        15      13        31
B3      120        14      12        37
Perianal disease n (%)  89 (26.0) 18 (29.5)  7 (21.1)  32 (31.4)
Frequent relapse n (%)                  126 (36.9) 24 (39.3)                  13 (39.4)  38 (37.3)
Extraintestinal manifestations n (%)                  117 (34.2) 17 (27.8)                  14 (42.4)  31 (30.4)
Arthritis n (%)  98 (28.7) 16 (26.2)                  14 (42.2)  24 (23.5)
Occular n (%)  18 (5.2)   1 (1.6)  2 (6.1)    4 (3.9)
Erythema nodosum/
Pyoderma n (%)  30 (8.8)   5 (8.2)  4 (12.1)    7 (6.9)
PSC n (%)  15 (4.4)   1 (1.6)       0    2 (1.9)
Steroid use/                  282 (82.4)/ 51 (83.6)/                  31 (93.9)/  88 (86.3)/
refractory n (%)  28 (9.3)   7 (13.7)  2 (16.1)    6 (6.8)
Azathioprine use/ refractory n (%)                  208 (60.8)/ 38 (62.3)/ 32 (97)1/  69 (67.6)/
 10 (4.8)   4 (10.5)  2 (11.1)    3 (4.3)
Operationn (%)                  128 (37.4) 27 (44.3)                  23 (69.7)1  53 (52.0)2
Smoking habits Never      191       44      21        65
Active      115       12       9        33
Previous         36        5       3         4
1P<0.001 between carriers and non-carriers; 2P<0.03 between carriers and non-carriers.
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Figure 1  Association between genetics and age at presentation in
patients with CD.
6.3 and 19.4%, which are in concordance with other studies
from Europe (6.7-12.5%, 3.3-6.1% and 6.6-16% in CD
and 3.5-6.9%, 0.6-3.0% and 1.0-4.4% in controls)[17,33].
The phenotype-genotype correlations in our cohort
were also similar to those reported in various European
countries[6,17,36]. Ileal involvement in Hungarian patients was
more frequent in NOD2 mutation carriers (81.6%), while
disease confined to the colon alone was less frequent (17.8%),
especially in patients with two alleles, in the presence of
SNP13 or TLR4 variant allele. Like in other countries, in
our study, carriage of variant NOD2/CARD15 allele was
associated with stricturing disease (30.8% vs 20.8%), while
variant alleles were less frequent in patients with inflammatory
disease. More patients with stricturing disease carried a
mutant NOD2/CARD15 allele (44.5%) than patients
without strictures (32.1%, P<0.01). Steroid use and efficacy
were similar in mutation carriers and non-carriers, but a
higher percentage of patients carrying NOD2/CARD15
variant allele needed azathioprine during the course of the
disease, especially in the presence of two risk alleles. There
are conflicting data on the association of NOD2/CARD15
mutations and need for surgery in CD patients: association[37]
and also lack of association[16,17] have been reported.
In a French follow-up study[18], ileal location was
associated with early development of stricturing disease while
a high number of flares was associated with a penetrating
pattern, but this was not affected by the presence of variant
NOD2/CARD15 allele. Active smoking was also associated
with early development of penetrating disease. In our study
there was no difference in the proportion of smokers
between carriers and non-carriers of NOD2/CARD15
variant allele.
The importance of TLR4 D299G polymorphism in CD
is less clear. In contrast to Franchimont et al.[27] who reported
a two-fold elevation in allele frequency of TLR4 D299G
(11% vs 5%, OR = 2.31), we found no difference in the
prevalence of TLR4 D299G polymorphism in CD patients
and controls, suggesting that this polymorphism is not
essential in the development of the disease. There is also
no difference in TLR4 allele frequency between IBD patients
and controls in concordance with the preliminary results of
the EC-IBD study group[28]. However, the rate of variant
allele is higher in the Hungarian controls compared to the
study of  Franchimont et al.[27]. We also found a tendency of
decreased frequency of the TLR4 D299G variant allele in
patients with familial disease (6% vs sporadic 13%, P = NS).
In our study, no clear-cut phenotype-genotype
associations were observed in TLR4 D299G carriers. The
presence of variant TLR4 allele tendencially associated with
early disease onset (P = 0.06), along with a gene-dosage
effect. The earliest onset (23 years) was observed in carriers
of both variant NOD2/CARD15 and TLR4 alleles (vs non-
carriers 30.2 years, P = 0.01). The presence of TLR4 variant
allele did not affect disease behavior (in patients with variant
TLR4 allele, stricturing disease was present in 33.3% of
NOD2 carriers vs 17.1% of NOD2/CARD15 non-carriers).
In summary, this is the first report on the prevalence
of NOD2/CARD15 mutations and TLR4 D299G
polymorphism in patients with CD from a Central Eastern
European country. It confirms that the risk for CD is increased
in carriers of R702W, R703C and 3020insC mutations,
while the presence of G908R or TLR4 D299G polymorphism
is not different from the controls. The presence of variant
NOD2/CARD15 alleles is associated with early disease
onset, ileal disease and stricturing disease behavior and
increases need for surgery, while the presence of TLR4
D299G variant allele exhibits a disease modifier effect.
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